More

• Crazy Finish But Comeback Continues Thursday, 9 Aug 2007 | 10:48 AM ET

  

  Wednesday was a crazy day for the markets, but when all was said and done The Dow finished 150 points higher and Blackstone (BX) formed the largest buyout fund ever. Is a steady comeback building this week for stocks? Here's the word on The Street.

• Sudden Death Thursday, 2 Aug 2007 | 7:34 PM ET

  Aecom, Marathon Oil, Northwest Airlines and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

• Big Pharma Is Bad Investing Tuesday, 12 Jun 2007 | 7:00 PM ET

  Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

• Lipitor: Loser Thursday, 24 May 2007 | 3:16 PM ET

  Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"

• Generics Unit of Germany's Merck Gets Four Final Bids Tuesday, 1 May 2007 | 12:55 AM ET

  Merck, Germany's drugs and chemicals group, received four final bids for its generics drugs business, sources familiar with the situation said on Monday.

• Ranbaxy Out of Merck KGaA Generic Hunt; Torrent In? Tuesday, 20 Mar 2007 | 3:29 AM ET

  Ranbaxy Laboratories is no longer in the running to buy the generic drug business of Germany's Merck, India's CNBC TV18 reported Tuesday. Ranbaxy withdrew from the second round of bidding for the business, the television station said.

• First Tysabri, Now Rituxan Tuesday, 19 Dec 2006 | 1:33 PM ET

  The same rare, but fatal viral infection that forced Biogen Idec and Elan to recall, and recently relaunch, the multiple sclerosis drug, Tysabri, may also be a side effect of Rituxan, also from Biogen Idec and Genentech. In an SEC filing -- not a press release -- and on the FDA website, the companies and the agency disclosed yesterday evening that two people with lupus died after taking Rituxan.